Spiro substituted compounds as angiogenesis inhibitors
US8163923B2 · kind B2 · utility
3Cited by
1References
11Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Feb 23, 2008 |
| Grant date | Apr 24, 2012 |
| Priority date | — |
| Expiry date | Sep 23, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D413/12
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to spiro (tetracarbon) substituted compound of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition of tyrosine kinases reducing effects in warm-blooded animals such as humans.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.